[ TRANSACTION RECORD ]

Merck & Co. Investment in Prometheus Biosciences — 2023

VERIFIED VECTOR ID: 001898 · tx-094-2
M SOURCE NODE — FUNDER
Merck & Co.
Healthcare United States
$10,800,000,000
EQUITY
16/06/2023
Q DESTINATION NODE — RECIPIENT
Prometheus Biosciences
Company United States
Amount (USD)
$10.8B
Flow Type
EQUITY
Transaction Date
16/06/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Merck & Co.
AUM 108000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity Prometheus Biosciences
Entity Type Company
Jurisdiction United States
Intelligence Note

Merck & Co. completed the 10.8 billion dollar acquisition of Prometheus Biosciences to bolster its immunology pipeline with a promising therapy for bowel disease. The transaction allows Merck to leverage its global scale to accelerate the development of precision medicines. This deal represents a significant institutional investment in the next generation of autoimmune treatments.

Σ
Primary Forensic Source https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/
✓ SOURCE LINKED